Survival after 17p− CLL diagnosis. (A) The rate of survival 3 years from the date of FISH diagnosis was 65%. (B) Survival after 17p− CLL diagnosis by institution. The rate of survival 3 years from the date of FISH diagnosis was 71% for patients from MDACC and 56% for patients from the Mayo Clinic (P = .43). (C) Survival after 17p− CLL diagnosis, effect of clone size. Survival was most favorable in patients with less than 25% deleted nuclei (3-year survival rate, 92%), intermediate in patients with 25% to 74% deleted nuclei (3-year survival rate, 67%), and least favorable in patients with 75% or more deleted nuclei (3-year survival rate, 40%; P = .001). (D) Model for survival after 17p− CLL diagnosis. Risk factors were Rai stage 1 or higher, unmutated IgV_H gene, and 17p loss in ≥ 25% of nuclei. Patients with 1 or fewer, 2, and 3 risk factors had 3-year survival rates of 95%, 74%, and 22%, respectively (P < .001). Sixteen patients were not assessable due to missing data on IgVH status.